Second-line treatment of metastatic gastric cancer: Current options and future directions
Dheepak Kanagavel, Mikhail Fedyanin, Alexey Tryakin, Sergei Tjulandin, Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Moscow 115478, Russia
Author contributions: Kanagavel D, Fedyanin M, Tryakin A and Tjulandin S contributed equally to this work; Tryakin A and Tjulandin S designed research; Kanagavel D and Fedyanin M performed research and analyzed data; and Kanagavel D, Fedyanin M, Tryakin A and Tjulandin S wrote the paper.
Conflict-of-interest statement: The authors have no conflict of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sergei Tjulandin, Professor, Department of Clinical Pharmacology and Chemotherapy, N. N. Blokhin Russian Cancer Research Center, Kashirskoe Shosse 24, Moscow 115478, Russia. firstname.lastname@example.org
Telephone: +7-499-3249844 Fax: +7-499-3249834
Received: April 28, 2015
Peer-review started: May 5, 2015
First decision: July 13, 2015
Revised: August 14, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: November 7, 2015